Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

Inclusion Criteria: * Healthy male subjects; 18 - 40 years of age * Body mass index between 18 and 27 kg/m2 * Written informed consent * Normal findings in medical history * Non-smoking Exclusion Criteria: * Regular intake of any medication including OTC drugs and herbals within 2 weeks before IMP administration * History of occlusive vascular diseases * History of vascular anomalies * History of coagulation disorders * History of diabetes mellitus (Type 1\&2) or pre-diabetes (i.e. HbA1c ≥ 5,7 %) * History of kidney disease * History of ketoacidosis * Impaired liver function (AST, ALT, gGT, bilirubin \>3 x ULN) * Impaired renal function (serum creatinine \> 1.3 mg/dl) * Any other relevant deviation from the normal range in clinical chemistry, haematology or urine analysis * HIV-1/2-Ab, HbsAg or HCV-Ab positive serology * Systolic blood pressure above 145 mmHg, diastolic blood pressure above 95 mmHg * Known allergy against any test agent under study and/or lactose intolerance * Regular daily consumption of more than on litre of xanthine-containing beverages or more than 40g alcohol * Participation in another clinical trial during the preceding 3 weeks